OTCMKTS:VIMGF

Vimian Group AB (publ) (VIMGF) Stock Forecast, Price & News

C$2.25

0.00 (0.00%)

(As of 09/27/2023 ET)

Compare

Today's Range: C$2.25
▼
C$2.25
50-Day Range: C$2.25
▼
C$3.32
52-Week Range: C$2.25
▼
C$2.25

Volume: N/A
Average Volume: 360 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Analyst Ratings Chart Competitors Headlines Short Interest

About Vimian Group AB (publ) (OTCMKTS:VIMGF) Stock

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

VIMGF Price History

30 days | 90 days | 365 days | Advanced Chart

VIMGF Stock News Headlines

July 19, 2023 | finance.yahoo.com

Notice to attend Extraordinary General Meeting in Anoto Group AB (publ)

July 19, 2023 | investing.com

Karnov Group AB (KARNO)

September 28, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 4, 2023 | finance.yahoo.com

Vimian's Interim Report for the First Quarter of 2023

April 4, 2023 | msn.com

BRIEF-Vimian Says Subsidiary Reaches Settlement Agreement Resolving Patent Litigation With Depuy Synthes

March 20, 2023 | finance.yahoo.com

Vimian’s Interim Report for the Second Quarter of 2022

March 20, 2023 | finance.yahoo.com

Vimian’s Interim Report for the Third Quarter of 2022

See More Headlines

Receive VIMGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vimian Group AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:VIMGF
CUSIP: N/A
CIK: N/A
Web: vimian.com
Phone: 46 7 36 26 88 86
Fax: N/A
Employees: 1,068
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Fredrik Ullman (Age 43)
Interim Chief Exec. Officer
Comp: $403.4k

Mr. Carl-Johan Zetterberg Boudrie (Age 45)
Chief Financial Officer

Ms. Maria Dahllof Tullberg (Age 42)
Head of IR, Communications & Sustainability

Mr. Carl-Johan Ehn (Age 49)
Gen. Counsel

Mr. Magnus Kjellberg (Age 50)
Chief Exec. Officer of Nextmune

Mr. Martin Bengtson
Head of M&A

Mr. Stefano Santarelli (Age 42)
Chief Exec. Officer of Indical Bioscience

Mr. Guy C. Sporri (Age 43)
Co-Chief Exec. Officer of Movora

Mr. Alireza Tajbakhsh (Age 40)
Head & CEO of VetFamily

Colleen Flesher (Age 47)
Co-Chief Exec. Officer of Movora

Key Competitors

View All Competitors

VIMGF Stock - Frequently Asked Questions

Should I buy or sell Vimian Group AB (publ) stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vimian Group AB (publ) in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIMGF shares.
View VIMGF analyst ratings or view top-rated stocks.
How have VIMGF shares performed in 2023?: Vimian Group AB (publ)'s stock was trading at C$3.20 at the start of the year. Since then, VIMGF shares have decreased by 29.7% and is now trading at C$2.25.
View the best growth stocks for 2023 here.
What is Vimian Group AB (publ)'s stock symbol?: Vimian Group AB (publ) trades on the OTCMKTS under the ticker symbol "VIMGF."

How do I buy shares of Vimian Group AB (publ)?: Shares of VIMGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vimian Group AB (publ)'s stock price today?: One share of VIMGF stock can currently be purchased for approximately C$2.25.
How many employees does Vimian Group AB (publ) have?: The company employs 1,068 workers across the globe.
How can I contact Vimian Group AB (publ)?: Vimian Group AB (publ)'s mailing address is Riddargatan 19, Stockholm 11457, Sweden, . The official website for the company is vimian.com. The company can be reached via phone at 46 7 36 26 88 86.

This page (OTCMKTS:VIMGF) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial